Skip to main content

Table 3 Hb, WBC and Plt values on the treatment day and hematotoxicity measured 2 months after Lu-PSMA therapy

From: Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Number Baseline Hb (g/dl) CTC Hb Baseline WBC (g/l) CTC WBC Baseline Plt (g/l) CTC Plt
1 9.6 0 7.4 0 352 0
2 11 0 7.1 0 322 0
3 9.0 0 4.7 0 181 1
4 11.7 3 3.3 2 62 0
5 11.5 0 5.9 0 170 0
6 14.5 0 8.8 0 234 0
7 11.4 0 8.0 0 295 0
8 12.2 1 10.1 0 313 0
9 9.3 0 3.4 1 99 2
10 9.9 0 7.3 0 321 0
  1. Patient 4, 9 and 10 had received blood transfusion prior to therapy because of low Hb levels
  2. CTC common toxicity criteria 2 months after therapy, Hb hemoglobulin, PLt platelet, WBC white blood cells